Clinical trials: Resistant Arterial Hypertension
Insulin Resistance, Obesity
Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity
A combination of generally regarded as safe (GRAS) compounds named GLY-LOW, which included: alpha lipoic acid, pyridoxamine, nicotinamide, piperine and thiamine, were examined in pre-clinical experiments.
- Conditions
- Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment
- Trial name
- NCT06242535
- Testing
- GLY-LOW
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hoskinson Health and Wellness Clinic
Hypertension
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy when given to metabolic syndrome patients with…
- Trial name
- AIMS (NCT00797316)
- Testing
- Aliskiren, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Novartis
Resistant Hypertension
Symplicity China Study
The Symplicity China study will evaluate the real-world long-term safety, efficacy, and durability of the Symplicity Spyral system in a population of approximately 500 renal denervation treated subjects with up to 36 months of…
- Trial name
- NCT07081243
- Testing
- Symplicity Spyral Renal Denervation System
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Medtronic Vascular
Metabolic Syndrome, Dyslipidemia
Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism
The purpose of this study is to investigate if daily consumption of barley beta-glucans effect lipid and glucose metabolism and alter intestinal microbiota composition in participants with metabolic syndrome or with high risk for…
- Conditions
- Metabolic Syndrome, Dyslipidemia, Obesity, Abdominal, Hyperglycemia
- Trial name
- NCT02041104
- Testing
- Bread with added beta-glucans
- Where
- 3 sites in Slovenia
- Volunteers
- 51 people
- Sponsor
- Mlinotest Zivilska Industrija d.d.
Hypertension
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.
- Trial name
- NCT06153693
- Testing
- lorundrostat Dose 1, lorundrostat Dose 2
- Where
- 184 sites in United States, Australia and 11 more
- Volunteers
- 1,083 people
- Sponsor
- Mineralys Therapeutics Inc.
Metabolic Syndrome, Hypertension
Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome
The purpose of this clinical research study is to learn if irbesartan is superior to hydrochlorothiazide relative to effects on insulin sensitivity and glucose metabolism in hypertensive patients with metabolic syndrome.
- Trial name
- NCT00110422
- Testing
- Irbesartan, Hydrochlorothiazide
- Where
- 25 sites in France, Germany and 4 more
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Essential Hypertension, Metabolic Syndrome
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
This is a multi-center, randomized, open-label, active comparator-controlled, phase 4 clinical trial to evaluate the blood pressure control of Telmisartan or Losartan in essential hypertensive patients with metabolic syndrome
- Trial name
- PRISTINE (NCT05843162)
- Testing
- Telmisartan, Losartan
- Volunteers
- 116 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Pulmonary Hypertension
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT00370214
- Where
- 54 sites in United States
- Volunteers
- 3,515 people
- Sponsor
- Actelion
PAH, Pulmonary Hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health…
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03626688
- Testing
- Ralinepag
- Where
- 209 sites in United States, Argentina and 31 more
- Volunteers
- 687 people
- Sponsor
- United Therapeutics
Prehypertension, Elevated Blood Pressure
Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure
This clinical study aims to assess the efficacy of TOTUM-854, a mix of 6 plant extracts, consumed twice a day on automated office blood pressure in subjects with moderately elevated blood pressure.
- Conditions
- Prehypertension, Elevated Blood Pressure, Blood Pressure, Metabolic Syndrome
- Trial name
- INSIGHT (NCT05469503)
- Testing
- TOTUM-854
- Where
- 10 sites in Bulgaria, France and 1 more
- Volunteers
- 410 people
- Sponsor
- Valbiotis
Resistant Hypertension
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs.
- Trial name
- Bax24 (NCT06168409)
- Testing
- Baxdrostat
- Where
- 102 sites in United States, Argentina and 20 more
- Volunteers
- 218 people
- Sponsor
- AstraZeneca
Hypertension
Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension
The primary objectives of this trial are (a) to demonstrate that the fixed-dose combination T40/A5 or the fixed-dose combination T80/A5 is superior in reducing blood pressure at eight weeks compared with A5 (b) to demonstrate…
- Trial name
- NCT00558428
- Testing
- fixed dose combination of telmisartan+amlodipine, amlodipine
- Where
- 129 sites in Belgium, Canada and 10 more
- Volunteers
- 1,098 people
- Sponsor
- Boehringer Ingelheim
Multivessel Coronary Artery Disease, Hypertension Resistant to Conventional Therapy
Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery diseasE
EMBRACE is a randomized, controlled, multicenter clinical study evaluating the effect of renal denervation on clinical adverse events in hypertensive patients undergoing staged percutaneous coronary intervention (PCI) for…
- Trial name
- EMBRACE (NCT07602790)
- Testing
- Renal denervation
- Volunteers
- 1,000 people
- Sponsor
- Ceric Sàrl
Hypertension, Metabolic Syndrome X
Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities
The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome.
- Trial name
- NCT00242814
- Testing
- Micardis, Amlodipine, Abdominal biopsy
- Where
- 31 sites in France
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Resistant Hypertension, Uncontrolled Hypertension
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
This is a global, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation with the OneShot Renal Denervation System in patients with uncontrolled hypertension.
- Conditions
- Resistant Hypertension, Uncontrolled Hypertension, Renal Artery Ablation
- Trial name
- RAPID II (NCT01939392)
- Testing
- Renal Denervation (OneShot™ Renal Denervation System)
- Where
- Italy
- Sponsor
- Medtronic Endovascular
Pulmonary Hypertension
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
- Trial name
- NCT00878878
- Testing
- Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GE Healthcare
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Truway Diagnostic Tools in Primary Care
This study evaluates the effectiveness of Truway Health-sourced portable diagnostic devices, including ultrasound and blood glucose monitors, in early detection of chronic conditions in outpatient primary care settings.
- Conditions
- Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute
- Trial name
- TruDxPC (NCT07209527)
- Testing
- Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Truway Health, Inc.
Hypertension, Concurrent Obesity
Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects
This study investigated the effects of LCZ696 on insulin sensitivity, lipolysis, and oxidative metabolism in obese hypertensive subjects.
- Trial name
- NCT01631864
- Testing
- LCZ696, amlodipine
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Vascular Diseases
A Study of the ReCor Medical Paradise System in Clinical Hypertension
RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct populations of…
- Trial name
- RADIANCE-HTN (NCT02649426)
- Testing
- The Paradise® Renal Denervation Ultrasound System
- Where
- 49 sites in United States, Belgium and 5 more
- Volunteers
- 282 people
- Sponsor
- ReCor Medical, Inc.
PAH
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.
- Trial name
- NCT04053543
- Testing
- CXA-10
- Where
- 37 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Complexa, Inc.